The AMARA (As Much As Reasonably Achievable) Study: Radioembolization of Large Inoperable Liver Tumors

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY

Subjects with large inoperable liver tumors defined as at least 1 lesion larger than 5cm in maximum diameter. For the purposes of the present study, we define the AMARA principle in intensified regional TARE as a planned irradiated tumor dose \>200Gy by the partition model. The purpose of the study is to evaluate the safety and efficacy of Y90 high dose radioembolization for the management of large inoperable liver tumors. In addition, to correlate the safety and efficacy with the post-treatment dosimetry analysis (by MIM Software Inc) based on 90Y-PET/CT imaging.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age \>18 yr

• Both sexes eligible for study

• Patients with primary or secondary liver tumors

• Liver dominant disease

• At least one lesion greater than 5.0 cm in maximum diameter

• Life-expectancy \> 3 months

• FLR \>40% or greater than 500mls

• Must be able to tolerate pre-treatment CT scan , DSA and 99mTc-MAA infusion and imaging with SPECT/CT scan

• Able to schedule and tolerate post-treatment Y90 PET/CT imaging

• Able to tolerate follow-up imaging with dynamic contrast CT liver phase or MRI with liver specific contrast at 3mo, 6mo, 9mo, 1yr, 2.0 yr, and 3.0 years.

Locations
Other Locations
Greece
University Hospital of Patras
RECRUITING
Pátrai
Contact Information
Primary
Konstantinos Katsanos, Professor
katsanos@med.upatras.gr
+306978225019
Time Frame
Start Date: 2024-02-05
Estimated Completion Date: 2027-02-05
Participants
Target number of participants: 100
Treatments
TARE group
(TARE)Transarterial radioembolization is a transcatheter intra-arterial procedure performed by the interventional radiologist for the treatment of primary and secondary hepatic cancers.
Related Therapeutic Areas
Sponsors
Leads: University Hospital of Patras

This content was sourced from clinicaltrials.gov

Similar Clinical Trials